Earnings Primer: What's on Deck for Rite Aid's Earnings
Upcoming SlideShare
Loading in...5
×
 

Earnings Primer: What's on Deck for Rite Aid's Earnings

on

  • 1,978 views

 

Statistics

Views

Total Views
1,978
Views on SlideShare
238
Embed Views
1,740

Actions

Likes
0
Downloads
0
Comments
0

9 Embeds 1,740

http://www.fool.com 1695
http://m.fool.com 24
http://barchartjson.websol.barchart.com 8
http://mockup.www.fool.com 5
http://www.dailyfinance.com 4
http://www.beaumontenterprise.com 1
http://www.greenwichtime.com 1
http://www.mysanantonio.com 1
http://translate.googleusercontent.com 1
More...

Accessibility

Upload Details

Uploaded via as Microsoft PowerPoint

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment

Earnings Primer: What's on Deck for Rite Aid's Earnings Earnings Primer: What's on Deck for Rite Aid's Earnings Presentation Transcript

  • Earnings Primer: What’s on Deck for Rite Aid’s Earnings
  • Is Rite Aid’s Margin Recovering? On June 5th, Rite Aid warned investors that its quarterly profit faced headwinds tied to lower than anticipated reimbursement rates and a delay in realizing the benefit of generic purchasing power through its new supply deal with McKesson. In that deal, McKesson assumed all sourcing and distribution responsibility for generics sold at Rite Aid stores. In the quarterly earnings report, investors should look for answers to these two important pharmacy margin questions: 1. Did the McKesson contract begin to support Rx margin in June? 2. Is there any timeline change to when Rite Aid expects to see the full benefit of the McKesson deal?
  • What was the impact of the ACA? Rite Aid reported earlier this month that same store sales during the quarter ending May increased 3.1% year-over-year. •Front end sales were flat. •Pharmacy sales were up 4.6%. The lift in pharmacy sales was driven by pricing, but total prescription count did climb by 2.3% in the past year, despite Rite Aid operating fewer stores. •Store count fell from 4,614 stores last year to 4,581 stores exiting May. One key question investors should be asking: •What percentage of that volume growth is thanks to new customers signed up under either ACA marketplace plans or Medicaid expansion?
  • Is the RediClinic rollout progressing? Rite Aid has trailed CVS and Walgreen in launching in-store clinics. •CVS operates more than 800 clinics. •Walgreen plans to operate more than 500 clinics by year end. •Rite Aid has limited its services primarily to immunizations. However, Rite Aid acquired RediClinic earlier this year in a bid to spark its health services platform. •RediClinic operates 30 clinics in Texas based H.E.B. grocery stores. •Rite Aid plans to take a two pronged approach to clinics. •Continue to expand RediClinic in non-Rite Aid stores. •Begin opening RediClinic in Rite Aid stores. Investors will hopefully get better insight into a timeline for Rite Aid’s RediClinic rollout during the quarterly earnings conference call.
  • Plans to enter new markets? Rite Aid struggles stem from its 2007 acquisition of Eckerd. That deal saddled Rite Aid with debt and cannibalized sales in overlapping markets. As part of Rite Aid’s return to profitability, the company has been focused on shuttering stores. •Rite Aid’s store count has dropped from 4,800 stores to less than 4,600 stores since 2010. •Rite Aid’s total debt has fallen from $6.25 billion in 2012 to $5.7 billion. The store closings and focus on profit has put Rite Aid on more solid ground, potentially opening up the door for the company to consider expanding into new markets like Texas (where it only operates RediClinics) and Florida. While Rite Aid is shrinking, CVS added 22 net new stores in Q1 and Walgreen plans to open a net 55 to 75 new stores this year. If Rite Aid is going to remain competitive, it will need to begin growing again.
  • Plans to return to enter new markets?
  • Will guidance be changed? Based on forward earnings estimates, Rite Aid’s valuation is in line with peers CVS and Walgreen. However, that could change if Rite Aid cuts its outlook even further. In June, Rite Aid lowered its FY15 EPS guidance from between $0.31 to $0.42 to between $0.30 and $0.40.
  • Fool-worthy final thoughts Few companies have outperformed Rite Aid over the past couple years, but Rite Aid continues to face some important challenges. While its debt has fallen, CVS and Walgreen are more financially fit. CVS and Walgreen also boast larger, national footprints that provide profit-friendly scale that Rite Aid may find tough to match. Additionally, CVS and Walgreen’s early lead in clinics provides a competitive advantage that could threaten Rite Aid’s customer base, particularly if newly insured patients turn away from hospital emergency rooms to competitors in- store clinics. If Rite Aid investors hope to see similar future returns to what they’ve recently enjoyed, they’re going to need to start seeing Rite Aid talk more about its growth plans for the future, rather than its restructuring plans for the present.
  • Will this stock be your next multi-bagger? Give us five minutes and we'll show how you could own the best stock for 2014. Every year, The Motley Fool's chief investment officer hand-picks one stock with outstanding potential. But it's not just any run-of-the-mill company. It's a stock perfectly positioned to cash in on one of the upcoming year's most lucrative trends. Last year his pick skyrocketed 134%. And previous top picks have gained upwards of 908%, 1,252% and 1,303% over the subsequent years! Believe me, you don't want to miss what could be his biggest winner yet! Just click here to download your free copy of "The Motley Fool's Top Stock for 2014" today.